Outlook Therapeutics, Inc. 8K

Outlook Therapeutics reported Q3 FY 2026 results, detailed launch preparations and commercial strategy following FDA approval of LYTENAVA for wet AMD, and disclosed a post-quarter public equity and warrant offering raising about $51.1 million in net proceeds.

On August 14, 2026, Outlook Therapeutics, Inc. reported its third quarter fiscal 2026 results and provided a business update highlighting recent FDA approval of LYTENAVA (bevacizumab-vikg), the only FDA-approved ophthalmic bevacizumab for wet age-related macular degeneration in the United States, and its ongoing preparations for a U.S. commercial launch by the end of calendar 2026, including payer engagement, pricing and reimbursement strategy, commercial supply build-out, and an intended HCPCS code submission by October 1, 2026; the company also noted continued European commercialization, an expectation that U.S. LYTENAVA sales could exceed $500 million annually by 2030, reported a GAAP net loss attributable to common stockholders of $20.3 million for the quarter ended June 30, 2026 (with an adjusted non-GAAP net loss of $10.9 million), and disclosed that subsequent to quarter end it completed a public offering of common stock and warrants for approximately $51.1 million in net proceeds.

Filing Facts

CIK

1649989

Ticker

-

Form

8K

Source Type

sec

Accession

0001104659-26-096478

Alert Tier

7